Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) EBITDA (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed EBITDA for 10 consecutive years, with -$113.3 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 7.38% to -$113.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$535.0 million, a 0.19% change, with the full-year FY2025 number at -$535.0 million, changed 0.19% from a year prior.
  • EBITDA was -$113.3 million for Q4 2025 at Ultragenyx Pharmaceutical, up from -$170.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$82.8 million in Q2 2021 to a low of -$225.1 million in Q3 2022.
  • A 5-year average of -$133.5 million and a median of -$134.3 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: plummeted 150.55% in 2022, then soared 35.53% in 2023.
  • Ultragenyx Pharmaceutical's EBITDA stood at -$102.6 million in 2021, then crashed by 41.99% to -$145.6 million in 2022, then rose by 16.33% to -$121.8 million in 2023, then dropped by 0.38% to -$122.3 million in 2024, then rose by 7.38% to -$113.3 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's EBITDA are -$113.3 million (Q4 2025), -$170.9 million (Q3 2025), and -$107.9 million (Q2 2025).